Choose Your language:
- Testimonials
-
great service thanks
- andrew
Read more »
- Articles
Our billing is certified by:
- News
-
- What’s best at beating swine flu, soap or gel?
- Commuters obsessively scrub their hands with gel
- Swine flu drug treatment will replace containment strategy
- More than 150 people have been diagnosed with swine flu over the past 24 hours as the rate of infection accelerates, pushing the total number of UK cases above 1,000
- Is the flu jab a waste of time?
- On balance, probably not
- Global flu pandemic would probably kill 62m, study says
- Around 62 million people in the world are likely to die if there is a flu pandemic and more than 70,000 of those deaths will be in the UK, according to a statistical analysis published today
- Vaccine against lethal strain of avian flu ready for human testing
- A British drug company is seeking permission to conduct the first human trials of an experimental vaccine against the avian flu virus
-
- World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) - MarketWatch (press release)
- World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)MarketWatch (press release)NEW YORK, Feb
- US FDA removes partial clinical hold on IDX184 of Idenix, allows enrollment of ... - pharmabiz.com
- US FDA removes partial clinical hold on IDX184 of Idenix, allows enrollment of
- Hepatitis C treatment with antivirals is effective: study - Los Angeles Times
- Los Angeles TimesHepatitis C treatment with antivirals is effective: studyLos Angeles TimesResearchers reported Wednesday that combining two antiviral medications was effective in stopping the infection in some patients who were not helped by the traditional treatment
- Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide ... - MarketWatch (press release)
- CitybizlistIdenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide
- Gilead tops table for antivirals - Pharma Times
- Gilead tops table for antiviralsPharma TimesWith combined sales from the top HIV treatment on the market, Atripla, and several other drugs, Gilead Sciences leads the antiviral market, closely followed by Bristol-Myers Squibb, Roche and Merck & Co
